Statin Use Linked to Lower PVR Risk

Clinical Report: Statin Use Linked to Lower PVR Risk

Overview

A retrospective study presented at the Retina Society 2026 indicates that systemic statin use is associated with a lower 1-year risk of proliferative vitreoretinopathy (PVR) and complex reoperation after retinal detachment (RD) repair. Statin users exhibited a 25% reduction in PVR risk compared to untreated controls.

Background

Proliferative vitreoretinopathy (PVR) is a significant complication following retinal detachment repair, occurring in 5% to 10% of cases. Current treatment options for PVR are limited, making the exploration of preventive strategies, such as statin therapy, clinically relevant. Understanding the potential role of statins in reducing PVR risk could inform future management approaches for patients undergoing RD repair.

Data Highlights

Group	PVR Risk	Complex RD Reoperation
Statin Users	3.8%	8.2%
Controls	4.7%	9.1%

Key Findings

Statin use was associated with a 25% lower risk of PVR (P=.003) after RD repair.
Complex RD reoperation rates were 8.2% in statin users versus 9.1% in controls (P=.018).
High-intensity statin use correlated with lower PVR risk (P=.031).
Lipophilic statins were linked to reduced PVR risk (P=.011), while hydrophilic statins were not.
Atorvastatin and simvastatin were associated with lower PVR risk, while rosuvastatin was not.

Clinical Implications

The findings suggest that systemic statin therapy may be beneficial in reducing the risk of PVR after RD repair. Further prospective studies are warranted to evaluate the timing and duration of statin therapy in this context.

Conclusion

This study highlights the potential role of statins in managing PVR risk following RD repair, warranting further investigation into their therapeutic application.